Literature DB >> 30430276

Review of Immune Therapies Targeting Ovarian Cancer.

Cong Ava Fan1, Jocelyn Reader1, Dana M Roque2.   

Abstract

OPINION STATEMENT: The rise of immunotherapy is the greatest advance in oncology to occur over the last several years, but applications in gynecologic malignancies lag behind other tumors. The term "immunotherapy" envelops monoclonal antibodies as receptor mediators, including immune checkpoint inhibitors (ICPI), cancer vaccines, and adoptive immunotherapies alone or in combination with other therapeutic approaches. The purpose of this review is to summarize the status of immunotherapy trials in ovarian cancer and to specifically highlight data published in the last 1-2 years.

Entities:  

Keywords:  Adoptive immunotherapy; Anti-angiogenic; Atezolizumab; Avelumab; BRCA 1/2 mutation; Bevacizumab; CAR-T cells; CTLA-4; Cancer vaccine; Folate receptor alpha; Folate-binding protein; HER2; Immune checkpoint inhibitors; Immunotherapy; Ipilimumab; MAGE; Mesothelin; Microsatellite instability; Mirvetuximab soravtansine; NK cells; NY-ESO; Nivolumab; Ovarian cancer; PARP inhibitors; PD-L1; PD-L2; PD1; Pembrolizumab; T cells; TILS; p53

Mesh：

Substances：

Year:  2018        PMID： 30430276     DOI： 10.1007/s11864-018-0584-3

Source DB:  PubMed          Journal:  Curr Treat Options Oncol        ISSN： 1534-6277


  49 in total

1.  IMGN853, a Folate Receptor-α (FRα)-Targeting Antibody-Drug Conjugate, Exhibits Potent Targeted Antitumor Activity against FRα-Expressing Tumors.

Authors:  Olga Ab; Kathleen R Whiteman; Laura M Bartle; Xiuxia Sun; Rajeeva Singh; Daniel Tavares; Alyssa LaBelle; Gillian Payne; Robert J Lutz; Jan Pinkas; Victor S Goldmacher; Thomas Chittenden; John M Lambert
Journal:  Mol Cancer Ther       Date:  2015-04-22       Impact factor: 6.261

2.  Maintenance therapy with autologous cytokine-induced killer cells in patients with advanced epithelial ovarian cancer after first-line treatment.

Authors:  Jun Liu; Hui Li; Shui Cao; Xinwei Zhang; Jinpu Yu; Jing Qi; Xiumei An; Wenwen Yu; Xiubao Ren; Xishan Hao
Journal:  J Immunother       Date:  2014 Feb-Mar       Impact factor: 4.456

3.  Phase I trial of "bi-shRNAi(furin)/GMCSF DNA/autologous tumor cell" vaccine (FANG) in advanced cancer.

Authors:  Neil Senzer; Minal Barve; Joseph Kuhn; Anton Melnyk; Peter Beitsch; Martin Lazar; Samuel Lifshitz; Mitchell Magee; Jonathan Oh; Susan W Mill; Cynthia Bedell; Candice Higgs; Padmasini Kumar; Yang Yu; Fabienne Norvell; Connor Phalon; Nicolas Taquet; Donald D Rao; Zhaohui Wang; Chris M Jay; Beena O Pappen; Gladice Wallraven; F Charles Brunicardi; David M Shanahan; Phillip B Maples; John Nemunaitis
Journal:  Mol Ther       Date:  2011-12-20       Impact factor: 11.454

4.  Improved Killing of Ovarian Cancer Stem Cells by Combining a Novel Chimeric Antigen Receptor-Based Immunotherapy and Chemotherapy.

Authors:  Rüdiger Klapdor; Shuo Wang; Ulrich Hacker; Hildegard Büning; Michael Morgan; Thilo Dörk; Peter Hillemanns; Axel Schambach
Journal:  Hum Gene Ther       Date:  2017-08-24       Impact factor: 5.695

5.  Natural cytotoxic activity of peripheral-blood lymphocytes and cancer incidence: an 11-year follow-up study of a general population.

Authors:  K Imai; S Matsuyama; S Miyake; K Suga; K Nakachi
Journal:  Lancet       Date:  2000-11-25       Impact factor: 79.321

Review 6.  T-cell target antigens across major gynecologic cancers.

Authors:  Alba Rodriguez-Garcia; Nicholas G Minutolo; John M Robinson; Daniel J Powell
Journal:  Gynecol Oncol       Date:  2017-04-02       Impact factor: 5.482

Review 7.  Natural Killer Cell-Based Immunotherapy in Gynecologic Malignancy: A Review.

Authors:  Locke D Uppendahl; Carly M Dahl; Jeffrey S Miller; Martin Felices; Melissa A Geller
Journal:  Front Immunol       Date:  2018-01-05       Impact factor: 7.561

8.  Primary human ovarian epithelial cancer cells broadly express HER2 at immunologically-detectable levels.

Authors:  Evripidis Lanitis; Denarda Dangaj; Ian S Hagemann; De-Gang Song; Andrew Best; Raphael Sandaltzopoulos; George Coukos; Daniel J Powell
Journal:  PLoS One       Date:  2012-11-26       Impact factor: 3.240

9.  CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation.

Authors:  M F Krummel; J P Allison
Journal:  J Exp Med       Date:  1995-08-01       Impact factor: 14.307

Review 10.  Natural Killer Cells: Angels and Devils for Immunotherapy.

Authors:  Beatriz Martín-Antonio; Guillermo Suñe; Lorena Perez-Amill; Maria Castella; Alvaro Urbano-Ispizua
Journal:  Int J Mol Sci       Date:  2017-08-29       Impact factor: 5.923
View more
  23 in total

1.  Tumor-expressed B7-H3 mediates the inhibition of antitumor T-cell functions in ovarian cancer insensitive to PD-1 blockade therapy.

Authors:  Dongli Cai; Jiaming Li; Dingfeng Liu; Shanjuan Hong; Qin Qiao; Qinli Sun; Pingping Li; Nanan Lyu; Tiantian Sun; Shan Xie; Li Guo; Ling Ni; Liping Jin; Chen Dong
Journal:  Cell Mol Immunol       Date:  2019-10-14       Impact factor: 11.530

2.  The Importance of Human Tissue Bioresources in Advancing Biomedical Research.

Authors:  Sameer Al Diffalha; Katherine C Sexton; Peter H Watson; William E Grizzle
Journal:  Biopreserv Biobank       Date:  2019-06       Impact factor: 2.300

Review 3.  Overview of imaging findings associated with systemic therapies in advanced epithelial ovarian cancer.

Authors:  Ezgi Guler; Daniel A Smith; Bhanusupriya Somarouthu; Rahul Gujrathi; Nikhil H Ramaiya; Sree Harsha Tirumani
Journal:  Abdom Radiol (NY)       Date:  2020-03

4.  Treatment with a retinoic acid-inducible gene I (RIG-I) agonist as monotherapy and in combination with pembrolizumab in patients with advanced solid tumors: results from two phase 1 studies.

Authors:  V Moreno; E Calvo; M R Middleton; F Barlesi; C Gaudy-Marqueste; A Italiano; E Romano; A Marabelle; E Chartash; K Dobrenkov; H Zhou; E C Connors; Y Zhang; M Wermke
Journal:  Cancer Immunol Immunother       Date:  2022-05-21       Impact factor: 6.630

Review 5.  Current Advances in PD-1/PD-L1 Blockade in Recurrent Epithelial Ovarian Cancer.

Authors:  Yuedi Zhang; Qiulin Cui; Manman Xu; Duo Liu; Shuzhong Yao; Ming Chen
Journal:  Front Immunol       Date:  2022-06-27       Impact factor: 8.786

6.  Targeting DNA Repair to Drive Immune Responses: It's Time to Reconsider the Strategy for Clinical Translation.

Authors:  Nobuyuki Takahashi; Ira Surolia; Anish Thomas
Journal:  Clin Cancer Res       Date:  2020-02-17       Impact factor: 12.531

Review 7.  Epithelial Ovarian Cancer and the Immune System: Biology, Interactions, Challenges and Potential Advances for Immunotherapy.

Authors:  Anne M Macpherson; Simon C Barry; Carmela Ricciardelli; Martin K Oehler
Journal:  J Clin Med       Date:  2020-09-14       Impact factor: 4.241

Review 8.  Not all cancers are created equal: Tissue specificity in cancer genes and pathways.

Authors:  Joy J Bianchi; Xin Zhao; Joseph C Mays; Teresa Davoli
Journal:  Curr Opin Cell Biol       Date:  2020-02-21       Impact factor: 8.382

9.  Expression of B7-H4 and IDO1 is associated with drug resistance and poor prognosis in high-grade serous ovarian carcinomas.

Authors:  Na Niu; Weiwei Shen; Yanping Zhong; Robert C Bast; Amir Jazaeri; Anil K Sood; Jinsong Liu
Journal:  Hum Pathol       Date:  2021-04-19       Impact factor: 3.466

10.  Overcome trastuzumab resistance of breast cancer using anti-HER2 chimeric antigen receptor T cells and PD1 blockade.

Authors:  Hongzhi Li; Weihua Yuan; Shufang Bin; Guang Wu; Panyuan Li; Min Liu; Jifeng Yang; Xiang Li; Kaiyan Yang; Haihua Gu
Journal:  Am J Cancer Res       Date:  2020-02-01       Impact factor: 5.942
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.